Evestia Clinical Limited is a registered limited company operating within the UK, established in 1996. The company’s primary focus is on providing comprehensive research and experimental development services to clients globally. Evestia specializes in supporting pharmaceutical, biotechnology, and medical device companies throughout the drug discovery and development lifecycle. Evestia’s core services encompass preclinical research, clinical trial management, and regulatory support, including formulation development, analytical testing, and CMC (Chemistry, Manufacturing, and Controls) activities. The company offers a range of bespoke solutions, from early-stage research to advanced preclinical studies, with a strong emphasis on supporting clients through IND (Investigational New Drug) and NDA (New Drug Application) submissions. Evestia’s international presence is significant, with a dedicated team and infrastructure supporting clients across North America, Europe, and Asia. The company employs a skilled workforce and actively seeks to expand its international reach. Evestia’s size is estimated to be around 50-100 employees, and its key focus is on delivering high-quality, reliable support. The company is classified as a type 72110 (Research and experimental development on biotechnology) and 86900 (Other human health activities).

Evestia Clinical Limited is a registered limited company operating within the UK, established in 1996. The company’s primary focus is on providing comprehensive research and experimental development services to clients globally. Evestia specializes in supporting pharmaceutical, biotechnology, and medical device companies throughout the drug discovery and development lifecycle. Evestia’s core services encompass preclinical research, clinical trial management, and regulatory support, including formulation development, analytical testing, and CMC (Chemistry, Manufacturing, and Controls) activities. The company offers a range of bespoke solutions, from early-stage research to advanced preclinical studies, with a strong emphasis on supporting clients through IND (Investigational New Drug) and NDA (New Drug Application) submissions. Evestia’s international presence is significant, with a dedicated team and infrastructure supporting clients across North America, Europe, and Asia. The company employs a skilled workforce and actively seeks to expand its international reach. Evestia’s size is estimated to be around 50-100 employees, and its key focus is on delivering high-quality, reliable support. The company is classified as a type 72110 (Research and experimental development on biotechnology) and 86900 (Other human health activities).